Biopharmaceutical/Pharmaceutical Manufacturing & Distribution
Strategic Profile
By controlling both the clinical development and the massive manufacturing infrastructure required to deliver metabolic treatments, Lilly has built a business model that is currently unrivaled in the industry. The company leverages its first-mover advantage and superior manufacturing scale to command over 60% of the metabolic health market share, with a multi-modal portfolio ranging from injectable tirzepatide to oral pills and the upcoming triple-agonist retatrutide.
Cyborg Score Rationale
Lilly has executed a $55 billion manufacturing overhaul since 2020, with major facilities in Lebanon, Indiana, and new sites in Germany and Ireland reaching operational milestones in the last six months, allowing it to move past supply shortages that plagued the GLP-1 market. Dominant market position with first-mover advantage in high-growth metabolic health market and upcoming oral obesity pill launch.
Top Insights
Mounjaro grew 110% to $7.4 billion and Zepbound grew 123% to $4.3 billion in Q4 2025, with combined sales representing over 60% of company revenue.
Mid-2026 launch of orforglipron, Lilly's daily obesity pill, could eliminate the need for injections for millions of patients.
Kwikpen delivery system launch in early 2026 is expected to capture larger international market share.
Lilly increased its U.S. obesity and diabetes drug market share to 60.5% in Q4 2025, while Novo Nordisk's share fell to 39.1%.
Named Competitors
Ozempic/Wegovy — Competitor GLP-1 diabetes and obesity treatments
Keytruda — Leading cancer immunotherapy
Diabetes/Obesity Portfolio — Emerging competitor in metabolic health
Recent Developments
(February 2026) Issued blockbuster financial guidance projecting 2026 revenue of $80-$83 billion, entering the trillion-dollar club.
(February 2026) Stock surged 10% following guidance announcement, solidifying position as world's most valuable healthcare company.
(Q4 2025) Revenue for the last three months of the year totaled $19.3 billion, a 43% increase from the same period a year ago.
(January 2026) Received FDA priority review voucher for orforglipron, cutting regulatory review time from 10-12 months to 1-2 months.
Open the full interactive Eli Lilly and Company report
30-page strategic research, 15-min analyst-debate audio briefing, full Cyborg Score breakdown across 11 dimensions.